InterMune's Pirfenidone Gets Advisory Committee Date; Panel Will Weigh Unmet Need Against Mixed Results
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA has granted the drug priority review status due to the unmet medical need it addresses.
You may also be interested in...
Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF
Though InterMune's pirfenidone still has the challenge of getting FDA approval based on mixed Phase III data using a not-yet validated primary endpoint, other drugs for idiopathic pulmonary fibrosis may face a clearer path to approvals following the Pulmonary-Allergy Drugs Advisory Committee March 9 review
Pirfenidone Panel Highlights Difficulty Of Selecting Primary Endpoint In IPF
Though InterMune's pirfenidone still has the challenge of getting FDA approval based on mixed Phase III data using a not-yet validated primary endpoint, other drugs for idiopathic pulmonary fibrosis may face a clearer path to approvals following the Pulmonary-Allergy Drugs Advisory Committee March 9 review
InterMune Files NDA For IPF Drug Despite Mixed Pivotal Trial Results
With IPF currently an unmet medical need in the U.S.; company seeks priority review; drug marketed in Japan by partner Shionogi.